Current Gastroenterology Reports

, Volume 2, Issue 1, pp 18–26 | Cite as

Population screening for hemochromatosis: Has the time finally come?

  • James C. Barton
  • Ronald T. Acton


Hemochromatosis refers to a group of common heritable disorders among Western Caucasians which increase susceptibility for development of iron overload and its complications. These consequences are preventable by early detection and simple, relatively inexpensive treatment. Screening of appropriate populations to detect hemochromatosis before iron overload occurs is both effective and cost-effective. The primary goal of screening should be the ongoing detection of persons with hemochromatosis, especially healthy individuals whose risk to develop iron overload is great, in a context that provides appropriate preventive treatment, education, and counseling. Although related issues warrant further study, implementation of well-designed screening programs for hemochromatosis should not be delayed.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Witte DL, Crosby WH, Edwards CQ, et al.: Practice Guideline Development Task Force of the College of American Pathologists: hereditary hemochromatosis. Clin Chim Acta 1996, 245:139–200.PubMedCrossRefGoogle Scholar
  2. 2.
    Cogswell ME, McDonnell SM, Khoury MJ, et al.: Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Ann Intern Med 1998, 129:971–979.PubMedGoogle Scholar
  3. 3.
    National Institutes of Health (NIH) Committee on Assessing Genetic Risks: Consensus statement: genetic testing for cystic fibrosis. In Assessing Genetic Risk: Implications for Health and Social Policy. Edited by Andrews LB, Holtzman NA, Motulsky AG. Bethesda, MD: NIH; 1997:15(4).Google Scholar
  4. 4.
    Feder JN, Gnirke A, Thomas W, et al.: A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996, 13:399–408.PubMedCrossRefGoogle Scholar
  5. 5.
    Beutler E, Gelbart T, West C, et al.: Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996, 22:187–194.PubMedCrossRefGoogle Scholar
  6. 6.
    Barton JC, Shih WWH, Sawada-Hirai R, et al.: Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis 1997, 23:135–145.PubMedCrossRefGoogle Scholar
  7. 7.
    The UK Haemochromatosis Consortium: A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut 1997, 41:841–844.CrossRefGoogle Scholar
  8. 8.
    Brissot P, Moirand R, Jouanolle A-M, et al.: A genotypic study of 217 unrelated probands diagnosed as genetic hemochromatosis on “classical” phenotypic criteria. J Hepatol 1999, 30:588–593.PubMedCrossRefGoogle Scholar
  9. 9.
    Adams PC, Barton JC, Bradley LA, et al.: Population screening for hemochromatosis: overview from a Consensus Panel. J Hepatol 1999, in press.Google Scholar
  10. 10.
    Adams PC: Population screening for hemochromatosis. Hepatology 1999, 29:1324–1327. A unique commentary on many practical issues raised by performing screening. This paper includes an excellent summary of genotypic screening programs for hemochromatosis in a variety of populations and settings.PubMedCrossRefGoogle Scholar
  11. 11.
    Motulsky AG: If I had a gene test, what would I have and who would I tell? Lancet 1999, 354:35–37. Writing in a relaxed first-person style, Motulsky offers thoughtful, lucid, commonsense advice about common and rare heritable disorders and the influences of age, ethnic background, available treatment, screening, and psychosocial issues. This paper highlights the variables that should be considered in selecting and undergoing phenotypic and genotypic tests for heritable disorders.CrossRefGoogle Scholar
  12. 12.
    McDonnell SM, Hover A, Gloe D, et al.: Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Am J Med 1999, 107:30–37.PubMedCrossRefGoogle Scholar
  13. 13.
    Merryweather-Clarke AT, Simonsen H, Shearman JD, et al.: A retrospective anonymous pilot study in screening newborns for HFE mutations in Scandinavian populations. Hum Mutat 1999, 13:154–159. These experts in hemochromatosis population genetics present data that support the contention that most of the World Health Organization criteria for population screening are fulfilled. The authors prefer genetic testing at the earliest feasible age and believe that negative psychologic and social implications of screening are minimal. They also take the stance that follow-up of C282Y heterozygotes is economically preferable.PubMedCrossRefGoogle Scholar
  14. 14.
    Olynyk J, Cullen DJ, Aquilia S, et al.: A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999, 341:718–724.PubMedCrossRefGoogle Scholar
  15. 15.
    Bradley JA, Johnson DD, Palomaki GE, et al.: Hereditary haemochromatosis mutation frequencies in the general population. J Med Screen 1998, 5:34–36.PubMedGoogle Scholar
  16. 16.
    Bismuth M, Larrey D, Blanc P, et al.: Phenotypic study of 52 homozygotes for the H63D mutation. In Proceedings of the World Congress on Iron Metabolism Bioiron. Italy: Sorrento, 1999:255.Google Scholar
  17. 17.
    Barton JC, Sawada-Hirai R, Rothenberg BE, Acton RT:Two novel missense HFE mutations (I105T and G93R) and confirmation of the S65C mutation in Alabama hemochromatosis probands. Blood Cells Mol Dis 1999, 25:146–154.CrossRefGoogle Scholar
  18. 18.
    Mura C, Raguenes O, Férec C: HFE mutation analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999, 93:2502–2505.PubMedGoogle Scholar
  19. 19.
    Pietrangelo A, Montosi G, Totaro A, et al.: Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999, 341:725–732.PubMedCrossRefGoogle Scholar
  20. 20.
    Proceedings of the World Congress on Iron Metabolism Bioiron. Sorrento, Italy; 1999:1–438.Google Scholar
  21. 21.
    Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ:Global prevalence of putative haemochromatosis mutations. J Med Genet 1997, 34:275–278.PubMedGoogle Scholar
  22. 22.
    Jezéquel P, Bargain M, Lellouche F, et al.: Allele frequencies of hereditary hemochromatosis gene mutations in a local population of west Brittany. Hum Genet 1998, 102:332–333.PubMedCrossRefGoogle Scholar
  23. 23.
    Carella M, D'Ambrosio L, Totaro A, et al.: Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet 1997, 60:828–832.PubMedGoogle Scholar
  24. 24.
    Marshall DS, Linfert DR, Tsongalis GJ: Prevalence of the C282Y and H63D polymorphisms in a multi-ethnic control population. Int J Mol Med 1999, 4:389–393.PubMedGoogle Scholar
  25. 25.
    Barton JC, Shih WWH, Sawada-Hirai R, et al.: Caucasian hemochromatosis mutation Cys282Tyr in African American iron overload [abstract]. J Invest Med 1997, 45:62a.Google Scholar
  26. 26.
    Monaghan KG, Rybicki BA, Shurafa M, Feldman GL: Mutation analysis of the HFE gene associated with hereditary hemochromatosis in African Americans. Am J Hematol 1998, 58:213–217.PubMedCrossRefGoogle Scholar
  27. 27.
    Israel S, Morag K, Brautbar C: Screening for the hemochromatosis associated C282Y gene mutation in the Israeli Jewish population. Hum Immunol 1999, 60(suppl 2):S66.Google Scholar
  28. 28.
    Asberg A, Hveem K, Thorstensen K, Bjerve K: Genotyping of 566 individuals with suspected hemochromatosis. In Proceedings of the World Congress on Iron Metabolism Bioiron. Sorrento, Italy;1999:239.Google Scholar
  29. 29.
    Konar J, Dufva IH, Olsson KS, Raha-Chowdhury R: Screening for hemochromatosis before the age of 35: time to accept these donors at blood banks? In Proceedings of the World Congress on Iron Metabolism Bioiron. Sorrento, Italy;1999:242.Google Scholar
  30. 30.
    Stave GM, Mignogna JJ, Powell GS, Hunt CM: Evaluation of a workplace hemochromatosis screening program. Am J Prev Med 1999, 16:303–306.PubMedCrossRefGoogle Scholar
  31. 31.
    Phatak P, Sham RL, Raubertas RF, et al.: Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med 1998, 129:954–961. This paper describes a model screening program that used phenotyping performed in an American healthcare delivery system. The authors summarize the results of their program, in which numerous community primary care physicians participated. However, their screening approach was not successful in identifying African Americans with iron overload.PubMedGoogle Scholar
  32. 32.
    McLaren GD, Hanekom DS, DuBord CJ, et al.: Identification of hemochromatosis homozygotes among U.S. military veterans attending primary care and subspecialty ambulatory clinics at a VA Medical Center: an interim report. In Proceedings of the World Congress on Iron Metabolism Bioiron. Sorrento, Italy; 1999:241.Google Scholar
  33. 33.
    Gomez A, Sbaiz L, Bertino E, et al.: Screening of the C282Y mutation in the HFE gene in Italy by Taqman technology. In Proceedings of the World Congress on Iron Metabolism Bioiron. Sorrento, Italy; 1999:238.Google Scholar
  34. 34.
    The American Society of Human Genetics Board of Directors and the American College of Medical Genetics Board of Directors: ASHG/ACMG Report. Points to consider: ethical, legal, and psychological implications of genetic testing in children and adolescents. Am J Hum Genet 1995, 57:1233–1241.Google Scholar
  35. 35.
    Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG, for the Committee on Assessing Genetic Risks, Division of Health Sciences Policy, Institute of Medicine: Assessing Genetic Risks: Implications for Health and Social Policy. Washington, DC: National Academy Press; 1994:89–91.Google Scholar
  36. 36.
    Willis G, Wimperis JZ, Smith KC, et al.: Haemochromatosis gene C282Y homozygotes in an elderly male population. Lancet 1999, 354:221–222.PubMedCrossRefGoogle Scholar
  37. 37.
    Ryan E, O'Keane C, Crowe J: Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis 1998, 24:428–432.PubMedCrossRefGoogle Scholar
  38. 38.
    Rossi E, Henderson S, Chin CYB, et al.: Genotyping as a diagnostic aid in genetic haemochromatosis. J Gastroenterol Hepatol 1999, 14:427–430.PubMedCrossRefGoogle Scholar
  39. 39.
    Davis JG: Population screening for hemochromatosis: the evolving role of genetic analysis. Ann Intern Med 1998, 129:905–907.PubMedGoogle Scholar
  40. 40.
    Bamberg R, Acton RT, Roseman JM, et al.: The effect of genetic risk information and health risk assessment on compliance with preventive behaviors. Health Educ 1990, 21:26–32.Google Scholar
  41. 41.
    Bassett ML, Leggett BA, Halliday JW, et al.: Analysis of the cost of population screening for haemochromatosis using biochemical and genetic markers. J Hepatol 1997, 27:517–524.PubMedCrossRefGoogle Scholar
  42. 42.
    Tavill AS: Screening for hemochromatosis: phenotyping or genotyping or both? Am J Gastroenterol 1999, 94:1430–1433.PubMedCrossRefGoogle Scholar
  43. 43.
    Bacon BR, Olynyk JK, Brunt EM, et al.: HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999, 130:953–962. Clinicians must often evaluate patients who have liver disease of uncertain cause. Bacon et al. demonstrate that approximately 15% of patients with C282Y homozygosity did not meet a previous diagnostic criterion for hemochromatosis, yet had liver disease. These findings indicate that genetic testing for hemochromatosis can be a useful diagnostic tool in such cases, and that clinical presentations of hemochromatosis other than “classical” ones may be relatively common.PubMedGoogle Scholar
  44. 44.
    Burke W, Thomson E, Khoury MJ, et al.: Hemochromatosis: gene discovery and its implications for population-based screening. JAMA 1998, 280:172–178.PubMedCrossRefGoogle Scholar
  45. 45.
    Cogswell ME, Burke W, McDonnell SM, Franks AL: Screening for hemochromatosis: a public health perspective. Am J Prev Med 1999, 16:134–140.PubMedCrossRefGoogle Scholar
  46. 46.
    Haddow JE, Bradley LA: Hereditary haemochromatosis: to screen or not. Conditions for screening are not yet fulfilled. Br Med J 1999, 319:531–532.Google Scholar
  47. 47.
    Merryweather-Clarke AT, Worwood M, Parkinson L, et al.: The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. Br J Haematol 1998, 101:369–373.PubMedCrossRefGoogle Scholar
  48. 48.
    Barton JC, Barton NH, Alford TJ: Diagnosis of hemochromatosis in a community hospital. Am J Med 1997, 103:498–503.PubMedCrossRefGoogle Scholar
  49. 49.
    Adams PC, Deugnier Y, Moirand R, Brissot P: The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997, 25:162–166.PubMedCrossRefGoogle Scholar
  50. 50.
    Edwards CQ, Griffen LM, Goldgar D, et al.: Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988, 318:1355–1362.PubMedCrossRefGoogle Scholar
  51. 51.
    McLaren CE, Gordeuk VR, Looker AC, et al.: Prevalence of heterozygotes for hemochromatosis in the white population of the United States. Blood 1995, 86:2021–2027.PubMedGoogle Scholar
  52. 52.
    Garry PJ, Montoya GD, Baumgartner RN, et al.: Impact of HLA-H mutations on iron stores in healthy elderly men and women. Blood Cells Mol Dis 1997, 23:277–287.PubMedCrossRefGoogle Scholar
  53. 53.
    DHG, Jazwinska EC, Cullen LM, Powell LW: Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998, 114:1003–1008.CrossRefGoogle Scholar
  54. 54.
    David V, Moirand R, Le Gall JY, et al.: Preliminary studies before systematic screening of hemochromatosis: prevalence and penetrance of C282Y homozygosity [abstract]. Am J Hum Genet 1999, 65S:A213.Google Scholar
  55. 55.
    Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG, for the Committee on Assessing Genetic Risks, Division of Health Sciences Policy, Institute of Medicine: Assessing Genetic Risks: Implications for Health and Social Policy. Washington, DC: National Academy Press; 1994:65–74.Google Scholar
  56. 56.
    Barton JC, McDonnell SE, Adams PC, et al.: Management of hemochromatosis. Ann Intern Med 1998, 129:932–939.PubMedGoogle Scholar
  57. 57.
    Barton JC, Rothenberg BE, Bertoli LF, Acton RT: Diagnosis of hemochromatosis in family members of probands: a comparison of phenotyping and HFE genotyping. Genet Med 1999, 1:89–93.PubMedCrossRefGoogle Scholar
  58. 58.
    Acton RT, Harman L: Genetic counseling for hemochromatosis. In Hemochromatosis: Genetics, Pathophysiology, Diagnosis, and Treatment. Edited by Barton JC, Edwards CQ. Cambridge, UK: Cambridge University Press; 1999:574–580.Google Scholar
  59. 59.
    College of American Pathologists (CAP): Chemistry Surveys 1998 and 1999. Northfield, IL: CAP; 1999.Google Scholar
  60. 60.
    Witte DL: Screening tests for hemochromatosis. In Hemochromatosis: Genetics, Pathophysiology, Diagnosis, and Treatment. Edited by Barton JC, Edwards CQ. Cambridge, UK: Cambridge University Press; 1999:519–524.Google Scholar
  61. 61.
    Laboratory Practice Committee: Standards and Guidelines: Clinical Genetics Laboratories. Bethesda, MD: The American College of Medical Genetics; 1993.Google Scholar
  62. 62.
    Schwartz MK: Genetic testing and the clinical laboratory improvement amendments of 1988: present and future. Clin Chem 1999, 45:739–45.PubMedGoogle Scholar
  63. 63.
    College of American Pathologists. ACMG/CAP Molecular Genetics Survey Set MGL-B. Northfield, IL: CAP; 1998.Google Scholar
  64. 64.
    NIH-DOE Working Group on Ethical, Legal, and Social Implications of Human Genome Research: Final Report of the Task Force on Genetic Testing: Promoting Safe and Effective Genetic Testing in the United States. Edited by Holtzman NA, Watson MS. Bethesda, MD; 1997:165–166.Google Scholar
  65. 65.
    Holtzman NA: Are genetic tests adequately regulated? Science 1999, 286:409.PubMedCrossRefGoogle Scholar
  66. 66.
    van't Spijker A, ten Kroode HF: Psychological aspects of genetic counselling: a review of the experience with Huntington's disease. Paient Educ Counsel 1997, 32:33–40. Some authors have suggested that testing persons who might develop genetic diseases, especially untreatable or potentially fatal ones, would precipitate negative psychosocial consequences, the adversity of which would overshadow the benefits of testing or screening. van't Spijker and ten Kroode demonstrate that genetic testing for Huntington disease, perhaps the most catastrophic of all welldescribed genetic disorders, is associated with few long-term negative psychosocial consequences.CrossRefGoogle Scholar
  67. 67.
    Ilen K, Williamson R: Should we genetically test everyone for haemochromatosis? J Med Ethics 1999, 25:209–214. These authors argue that population-based genetic screening for hemochromatosis should be supported when a number of contentious issues are addressed. Further, they consider hemochromatosis to be the paradigm of a disorder in which an ethical and clinical imperative exists to encourage presymptomatic DNA testing for all individuals in ethnically relevant communities.CrossRefGoogle Scholar
  68. 68.
    McDonnell SM, Witte DL, Cogswell DL, et al.: Strategies to increase detection of hemochromatosis. Ann Intern Med 1998, 129:987–992.PubMedGoogle Scholar
  69. 69.
    Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS: Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) Guidelines. Circulation 1998, 98:851–855.PubMedGoogle Scholar
  70. 70.
    Chambers DC: Ten keys to life insurance industry success with genetic testing. In Genetic Testing: Implications for Insurance. Schaumburg, IL: The Actuarial Foundation; 1997:65–68.Google Scholar
  71. 71.
    Alper JA, Geller LN, Barash CI, et al.: Genetic discrimination and screening for hemochromatosis. J Public Health Policy 1994, 15:345–358.PubMedCrossRefGoogle Scholar
  72. 72.
    Reilly PR: Rethinking risks to human subjects in genetic research. Am J Hum Genet 1998, 63:682–685.PubMedCrossRefGoogle Scholar
  73. 73.
    The Health Insurance Portability and Accountability Act, 104 Public Law No. 104-191, 110STAT, 1936; 1996.Google Scholar
  74. 74.
    104STAT. 327(1991). For sections of the Americans with Disabilities Act relating to employment, see 42 U.S.C.A. Sections 12101-12117 (suppl 1992).Google Scholar
  75. 75.
    Lehpamer PJ: Principles of risk: health, disability, life. In Genetic Testing: Implications for Insurance. Schaumburg, IL:The Actuarial Foundation; 1997:1–9.Google Scholar
  76. 76.
    Christianson DJ: Actuarial implications of genetic testing. In Genetic Testing: Implications for Insurance. Schaumburg, IL: The Actuarial Foundation; 1997:127–131.Google Scholar
  77. 77.
    U.S. Preventive Services Task Force: Guide to Clinical Preventive services, edn 2. Baltimore, MD: Williams & Wilkins; 1996:39–55.Google Scholar

Copyright information

© Current Science Inc. 2000

Authors and Affiliations

  • James C. Barton
    • 1
  • Ronald T. Acton
    • 2
  1. 1.Southern Iron Disorders CenterBirminghamUSA
  2. 2.Department of MedicineUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations